Anders Månsson recently visited BioStock Studio to talk about his new role as CEO of Oncoinvent. The full interview is available at: Interview with Anders Månsson
Menu
Onc File published (year): 2023
Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed
Presentation on September 30, 2023
Oncoinvent will present at the 13th PSOGI Congress: CMO, Kari Myren will present at the poster session: Title: “Novel radiopharmaceutical for intraperitoneal treatment of peritoneal metastasis from colorectal and ovarian cancer after complete surgical resection”, Dr. Stein Gunnar Larsen, Oslo University Hospital will also present an oral abstract: Title: “18-month safety and efficacy after intraperitoneal … Read more
Oncoinvent be represented by CMO, Dr. Kari Myren at the 2023 ESGO congress. There will also be a mini oral presentation on the theme “First Experience With Intra-Abdominal 224Radium-Labelled Microparticles (Radspherin) After Cytoreductive Surgery For Peritoneal Metastasis In Recurrent Epithelial Ovarian Cancer (Phase 1 Study)” by Dr. Els Van Nieuwenhuysen, University Hospital Leuven, Leuven, Belgium
Anders brings nearly 30 years of international and diverse experience in oncology-focused drug development and commercialization.
Oncoinvent will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.
Median PFS (progression free survival) was not reached at 15 months, and no patients at recommended dose of 7 MBq had peritoneal recurrences
All dose levels of Radspherin®, including recommended dose of 7 MBq, were well tolerated at 15 months with no serious adverse events related to Radspherin® reported
Radspherin® is currently being evaluated in two ongoing Phase 1/2A trials for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer
Poster discussion session on June 5, 2023 at 1:15 p.m. ET
Publications highlight the safety and tolerability of Radspherin® for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.
